Patients can start and stay on Humalog U-200 KwikPen as their insulin needs increase*
*Option for patients who require >20 units of mealtime insulin/day.
Bioequivalence – with half the volume
Humalog U-200 is bioequivalent* to Humalog U-100; therefore you should expect similar efficacy and safety as Humalog U-1001. Humalog U-200 KwikPen delivers the same dose of insulin in half the liquid volume.1
Humalog U-200 was bioequivalent* to Humalog U-100 after subcutaneous administration of a single 20-unit dose in healthy subjects. Time to maximum concentration was also similar between formulations.
Select Important Safety Information
Instruct patients to always check the insulin label before each injection to avoid medication errors. Do NOT transfer Humalog U-200 from the Humalog KwikPen to a syringe as overdose and severe hypoglycemia can occur.
Delivers the same dose in half the liquid volume of Humalog U-100 KwikPen
Humalog 200 units/mL is twice the concentration of Humalog U-100 mealtime, rapid-acting insulin.
Humalog and Insulin Lispro Injection are rapid-acting insulin analogs indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. Humalog Mix75/25 and Humalog Mix50/50, and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 are mixtures of intermediate-acting and rapid-acting human insulin analogs indicated to improve glycemic control in patients with diabetes mellitus.
Limitations of Use: The proportions of rapid-acting and intermediate-acting insulins in Humalog Mix75/25 and Humalog Mix50/50, and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 are fixed and do not allow for basal versus prandial dose adjustments.